MAGNIFY: A phase 3B, randomized trial of lenalidomide plus rituximab induction and maintenance therapy followed by lenalidomide single-agent versus rituximab maintenance in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL).
David J Andorsky
Research Funding - Celgene
Patricia E Cataruozolo
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Jorge L Mouro
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Ju Li
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Pierre Fustier
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Kenneth A. Foon
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Jeff Porter Sharman
Consultant or Advisory Role - Celgene
Research Funding - Celgene